GIVLAARI Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Givlaari, and what generic alternatives are available?
Givlaari is a drug marketed by Alnylam Pharms Inc and is included in one NDA. There are twelve patents protecting this drug.
This drug has three hundred and twenty-four patent family members in forty-three countries.
The generic ingredient in GIVLAARI is givosiran sodium. One supplier is listed for this compound. Additional details are available on the givosiran sodium profile page.
DrugPatentWatch® Generic Entry Outlook for Givlaari
Givlaari was eligible for patent challenges on November 20, 2023.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 3, 2034. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for GIVLAARI?
- What are the global sales for GIVLAARI?
- What is Average Wholesale Price for GIVLAARI?
Summary for GIVLAARI
| International Patents: | 324 |
| US Patents: | 12 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 1 |
| Drug Prices: | Drug price information for GIVLAARI |
| What excipients (inactive ingredients) are in GIVLAARI? | GIVLAARI excipients list |
| DailyMed Link: | GIVLAARI at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for GIVLAARI
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for GIVLAARI
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Alnylam Pharmaceuticals | Phase 3 |
Pharmacology for GIVLAARI
| Drug Class | Aminolevulinate Synthase 1-directed RNA Interaction Small Interfering RNA |
| Physiological Effect | Decreased RNA Integrity |
US Patents and Regulatory Information for GIVLAARI
GIVLAARI is protected by twelve US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of GIVLAARI is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting GIVLAARI
Compositions and methods for inhibiting expression of the ALAS1 gene
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE HEPATIC PORPHYRIA
Compositions and methods for inhibiting expression of the ALAS1 gene
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE HEPATIC PORPHYRIA
Glycoconjugates of RNA interference agents
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE HEPATIC PORPHYRIA
Therapeutic compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods for inhibiting expression of the ALAS1 gene
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE HEPATIC PORPHYRIA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Carbohydrate conjugates as delivery agents for oligonucleotides
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE HEPATIC PORPHYRIA
Carbohydrate conjugates as delivery agents for oligonucleotides
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE HEPATIC PORPHYRIA
Compositions and methods for inhibiting expression of the ALAS1 gene
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE HEPATIC PORPHYRIA
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods for inhibiting expression of the ALAS1 gene
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE HEPATIC PORPHYRIA
Therapeutic compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting GIVLAARI
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
INDICATED FOR THE TREATMENT OF ADULTS WITH ACUTE HEPATIC PORPHYRIA (AHP)
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for GIVLAARI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | ⤷ Sign Up | ⤷ Sign Up |
| Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | ⤷ Sign Up | ⤷ Sign Up |
| Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | ⤷ Sign Up | ⤷ Sign Up |
| Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | ⤷ Sign Up | ⤷ Sign Up |
| Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for GIVLAARI
When does loss-of-exclusivity occur for GIVLAARI?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 7920
Patent: COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN DEL GEN SINTASA 1 DE ÁCIDO 5-AMINOLEVULÍNICO (ALAS1)
Estimated Expiration: ⤷ Sign Up
Patent: 8658
Patent: COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN DEL GEN ALAS1
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 14331604
Patent: Compositions and methods for inhibiting expression of the ALAS1 gene
Estimated Expiration: ⤷ Sign Up
Patent: 20286311
Patent: Compositions and methods for inhibiting expression of the ALAS1 gene
Estimated Expiration: ⤷ Sign Up
Patent: 23266354
Patent: Compositions and methods for inhibiting expression of the ALAS1 gene
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2016007226
Patent: composições e métodos para inibição da expressão do gene alas1
Estimated Expiration: ⤷ Sign Up
Patent: 2020001264
Patent: ÁCIDO RIBONUCLEICO DE FITA DUPLA (DSRNA) PARA INIBIÇÃO DA EXPRESSÃO DE ALAS1, COMPOSIÇÃO FARMACÊUTICA PARA INIBIÇÃO DA EXPRESSÃO DE UM GENE ALAS1, MÉTODOS DE INIBIÇÃO DA EXPRESSÃO DE ALAS1 EM UMA CÉLULA E PARA DIMINUIR UM NÍVEL DE UMA PORFIRINA OU DE UM PRECURSOR DE PORFIRINA EM UMA CÉLULA, USOS DE UM DSRNA, MÉTODO PARA AVALIAR O NÍVEL DE MRNA DE ALAS1 EXTRACELULAR EM CIRCULAÇÃO EM UM INDIVÍDUO, COMPOSIÇÃO E USO DA MESMA
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 25357
Patent: COMPOSITIONS ET METHODES PERMETTANT D'INHIBER L'EXPRESSION DU GENE ALAS1 (COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE)
Estimated Expiration: ⤷ Sign Up
Patent: 27061
Patent: COMPOSITIONS ET METHODES PERMETTANT D'INHIBER L'EXPRESSION DU GENE ALAS1 (COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 16000772
Patent: Composiciones y métodos para inhibir la expresión del gen alas1
Estimated Expiration: ⤷ Sign Up
Patent: 18000158
Patent: Composiciones y métodos para inhibir la expresión del gen alas1 (divisional de solicitud 20160772)
Estimated Expiration: ⤷ Sign Up
China
Patent: 5980559
Patent: 用于抑制ALAS1基因表达的组合物与方法 (COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ALAS1 GENE)
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 160195
Patent: COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN DEL GEN ALAS 1
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0200822
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 22975
Estimated Expiration: ⤷ Sign Up
Patent: 20029
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 52628
Estimated Expiration: ⤷ Sign Up
Dominican Republic
Patent: 016000073
Patent: COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN DEL GEN ALAS1
Estimated Expiration: ⤷ Sign Up
Patent: 022000085
Patent: COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN DEL GEN ALAS1
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 6477
Patent: КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНА ALAS1 (COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE)
Estimated Expiration: ⤷ Sign Up
Patent: 1690685
Patent: КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНА ALAS1
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 52628
Patent: COMPOSITIONS ET MÉTHODES PERMETTANT D'INHIBER L'EXPRESSION DU GÈNE ALAS1 (COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE)
Estimated Expiration: ⤷ Sign Up
Patent: 93463
Patent: COMPOSITIONS ET PROCÉDÉS D'INHIBITION D'EXPRESSION DU GÈNE ALAS1 (COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE)
Estimated Expiration: ⤷ Sign Up
Guatemala
Patent: 1600066
Patent: COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN DEL GEN ALAS1
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 21738
Patent: 抑制 基因表現的組合物及方法 (COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE ALAS1)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 49227
Estimated Expiration: ⤷ Sign Up
Patent: 000034
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 4749
Patent: תכשירים ושיטות לעיכוב ביטוי של גן ה alas1 (Compositions and methods for inhibiting expression of the alas1 gene)
Estimated Expiration: ⤷ Sign Up
Patent: 2747
Patent: תכשירים ושיטות לעיכוב ביטוי של גן ה alas1 (Compositions and methods for inhibiting expression of the alas1 gene)
Estimated Expiration: ⤷ Sign Up
Patent: 2726
Patent: תכשירים ושיטות לעיכוב ביטוי של גן ה alas1 (Compositions and methods for inhibiting expression of the alas1 gene)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 13227
Estimated Expiration: ⤷ Sign Up
Patent: 89254
Estimated Expiration: ⤷ Sign Up
Patent: 16539623
Patent: ＡＬＡＳ１遺伝子の発現を阻害する組成物および方法
Estimated Expiration: ⤷ Sign Up
Patent: 20096582
Patent: ＡＬＡＳ１遺伝子の発現を阻害する組成物および方法 (COMPOSITION AND METHOD FOR INHIBITING EXPRESSION OF ALAS1 GENE)
Estimated Expiration: ⤷ Sign Up
Patent: 23120219
Patent: ＡＬＡＳ１遺伝子の発現を阻害する組成物および方法 (COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE)
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 052628
Estimated Expiration: ⤷ Sign Up
Patent: 2020527
Estimated Expiration: ⤷ Sign Up
Patent: 52628
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 3490
Patent: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
Estimated Expiration: ⤷ Sign Up
Patent: 7646
Patent: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 16004319
Patent: COMPOSICIONES Y METODOS PARA INHIBIR LA EXPRESION DEL GEN DE SINTASA DE ACIDO 5'-AMINOLEVULINICO 1 (ALAS1). (COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE.)
Estimated Expiration: ⤷ Sign Up
Patent: 22001017
Patent: COMPOSICIONES Y METODOS PARA INHIBIR LA EXPRESION DEL GEN DE SINTASA DE ACIDO 5'-AMINOLEVULINICO 1 (ALAS1). (COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE.)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 000
Patent: Compositions et méthodes permettant d'inhiber l'expression du gène alas1
Estimated Expiration: ⤷ Sign Up
Netherlands
Patent: 1061
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 8995
Patent: Compositions and methods for inhibiting expression of the alas1 gene
Estimated Expiration: ⤷ Sign Up
Patent: 7749
Patent: Compositions and methods for inhibiting expression of the alas1 gene
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 161130
Patent: COMPOSICIONES Y METODOS PARA INHIBIR LA EXPRESION DEL GEN ALAS1
Estimated Expiration: ⤷ Sign Up
Patent: 211249
Patent: PRODUCTO DE FARMACO DE siARN PARA INHIBIR LA EXPRESION DE ALAS1 Y COMPOSICION QUE LO COMPRENDE
Estimated Expiration: ⤷ Sign Up
Philippines
Patent: 016500574
Patent: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 52628
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 52628
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 201910929Q
Patent: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
Estimated Expiration: ⤷ Sign Up
Patent: 201602631X
Patent: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 52628
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1602931
Patent: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
Estimated Expiration: ⤷ Sign Up
Patent: 1802919
Patent: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2307389
Estimated Expiration: ⤷ Sign Up
Patent: 2469850
Estimated Expiration: ⤷ Sign Up
Patent: 160079793
Patent: ＡＬＡＳ1 유전자의 발현을 억제하기 위한 조성물 및 방법 (COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE)
Estimated Expiration: ⤷ Sign Up
Patent: 210122877
Patent: ＡＬＡＳ1 유전자의 발현을 억제하기 위한 조성물 및 방법 (1 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE)
Estimated Expiration: ⤷ Sign Up
Patent: 220159478
Patent: ＡＬＡＳ1 유전자의 발현을 억제하기 위한 조성물 및 방법 (1 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 04510
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 94080
Estimated Expiration: ⤷ Sign Up
Patent: 68330
Estimated Expiration: ⤷ Sign Up
Patent: 1524991
Patent: Compositions and methods for inhibiting expression of the ALAS1 gene
Estimated Expiration: ⤷ Sign Up
Patent: 2106697
Patent: Compositions and methods for inhibiting expression of the ALAS1 gene
Estimated Expiration: ⤷ Sign Up
Patent: 2310853
Patent: Compositions and methods for inhibiting expression of the ALAS1 gene
Estimated Expiration: ⤷ Sign Up
Tunisia
Patent: 16000114
Patent: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE.
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 4961
Patent: ДВОНИТКОВА РИБОНУКЛЕЇНОВА КИСЛОТА (dsRNA) ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ALAS1 (COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE)
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering GIVLAARI around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 02055693 | ⤷ Sign Up | |
| Germany | 19956568 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 2009073809 | ⤷ Sign Up | |
| Cyprus | 1119491 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 2006032041 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for GIVLAARI
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3052628 | 2020029 | Norway | ⤷ Sign Up | PRODUCT NAME: GIVOSIRAN ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV; REG. NO/DATE: EU/1/20/1428 20200306 |
| 3052628 | 724 | Finland | ⤷ Sign Up | |
| 3052628 | LUC00175 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: GIVOSIRAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/20/1428 20200304 |
| 3052628 | CA 2020 00042 | Denmark | ⤷ Sign Up | PRODUCT NAME: GIVOSIRAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/20/1428 20200304 |
| 3052628 | 122020000045 | Germany | ⤷ Sign Up | PRODUCT NAME: GIVOSIRAN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/20/1428 20200302 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
